1. Bendamustine: something old, something new

   • Nishant Tageja
   • Jasdeepa Nagi

   Mini Review 08 April 2010 Pages: 413 - 423

   

2. Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance

   • Yong Wha Moon
   • Joo Hyuk Sohn
   • Joo-Hang Kim

   Original Article 15 December 2009 Pages: 425 - 431

3. GCS induces multidrug resistance by regulating apoptosis-related genes in K562/AO2 cell line

   • Yan Liu
   • Ke-Ming Xie
   • Ping Xie

   Original Article 24 November 2009 Pages: 433 - 439

   

4. A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors

   • E. Gabriela Chiorean
   • Srikar Malireddy
   • Christopher J. Sweeney

   Original Article 29 November 2009 Pages: 441 - 448

   

5. Phase II study of carboplatin combined with weekly docetaxel in patients with advanced non-small cell lung cancer

   • Lian Jiang
   • Dao-yuan Wang
   • Dan-feng Wang

   Original Article 24 November 2009 Pages: 449 - 453

   

6. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines

   • Ying Wang
   • Arun K. Rishi
   • Anil Wali

   Original Article 04 December 2009 Pages: 455 - 466

   

7. Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies

   • Liangao Hu
   • Weimin Miao
   • Gerald Batist

   Original Article 26 November 2009 Pages: 467 - 474

   

8. Differential apoptotic response of human cancer cells to organoselenium compounds

   • Maiko Suzuki
   • Manabu Endo
   • Hidemi Rikiishi

   Original Article 26 November 2009 Pages: 475 - 484

   

9. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma

   • Rikke L. Hedeland
   • Kristian Hvidt
   • Kjeld Schmiegelow

   Original Article 03 December 2009 Pages: 485 - 491

   

10. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer

    • Jun Liang
    • Tao Jiang
    • Wei-wei Qi

    Original Article 04 December 2009 Pages: 493 - 500

    

11. Influence of DNA repair RAD51 gene variants in overall survival of non-small cell lung cancer patients treated with first line chemotherapy

    • Augusto Nogueira
    • Raquel Catarino
    • Rui Medeiros

    Original Article 04 December 2009 Pages: 501 - 506

    

12. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status

    • Yeon Hee Park
    • Soohyeon Lee
    • Young-Hyuck Im

    Original Article 03 December 2009 Pages: 507 - 516

    

13. Toxicity against gastric cancer cells by combined treatment with 5-fluorouracil and mitomycin c: implication in oxidative stress

    • Toshiyuki Matsunaga
    • Yoshitaka Tsuji
    • Akira Hara

    Original Article 05 December 2009 Pages: 517 - 526

    

14. A phase II study of induction chemotherapy with gemcitabine plus S-1 followed by chemoradiotherapy for locally advanced pancreatic cancer

    • Kohei Nakachi
    • Junji Furuse
    • Satoshi Shimizu

    Original Article 05 December 2009 Pages: 527 - 534

    

15. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells

    • Andrew J. Massey
    • Douglas S. Williamson
    • Mike Wood

    Original Article 13 December 2009 Pages: 535 - 545

    

16. Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines

    • Sara Nannizzi
    • Gareth J. Veal
    • Romano Danesi

    Original Article Open access 18 December 2009 Pages: 547 - 558

    

17. Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma

    • Fotios Loupakis
    • Gianluca Masi
    • Alfredo Falcone

    Original Article 17 March 2010 Pages: 559 - 566

    

18. Anemia response and safety to epoetin-beta treatment in patients with neoadjuvant therapy prior to primary digestive tract tumor surgery

    • Antonio Gómez
    • Mercedes Salgado
    • Rafael López

    Original Article 12 December 2009 Pages: 567 - 573

    

19. Synergistic interactions between aminoflavone, paclitaxel and camptothecin in human breast cancer cells

    • Kathryn E. Reinicke
    • Mary J. Kuffel
    • Matthew M. Ames

    Original Article 11 December 2009 Pages: 575 - 583

    

20. Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multi-drug-resistant cancer cells

    • Seema-Maria Nathwani
    • Stephen Butler
    • Daniela M. Zisterer

    Original Article 18 December 2009 Pages: 585 - 596

    

21. Ixabepilone plus capecitabine for Chinese patients with metastatic breast cancer progressing after anthracycline and taxane treatment

    • Jiayu Wang
    • Ying Fan
    • Binghe Xu

    Clinical Trial Report 21 May 2010 Pages: 597 - 603

    

22. Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis

    • Mohamed Bouchahda
    • Abdoulaye Karaboué
    • Francis Lévi

    Short Communication 02 April 2010 Pages: 605 - 609

    

23. The histone deacetylase inhibitor vorinostat induces calreticulin exposure in childhood brain tumour cells in vitro

    • Jürgen Sonnemann
    • Stephanie Greßmann
    • James F. Beck

    Short Communication 10 March 2010 Pages: 611 - 616

    

24. MDR1 C2005T polymorphism changes substrate specificity

    • Lijuan Liu
    • Lan Fan
    • Honghao Zhou

    Short Communication 23 March 2010 Pages: 617 - 623